Quantum Financial Advisors LLC Acquires New Position in Kenvue Inc. $KVUE

Quantum Financial Advisors LLC bought a new position in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 33,629 shares of the company’s stock, valued at approximately $580,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank purchased a new position in Kenvue during the second quarter worth approximately $537,418,000. Independent Franchise Partners LLP increased its stake in shares of Kenvue by 233.4% in the 2nd quarter. Independent Franchise Partners LLP now owns 31,265,574 shares of the company’s stock worth $654,388,000 after acquiring an additional 21,886,537 shares during the last quarter. Van ECK Associates Corp increased its stake in shares of Kenvue by 101.3% in the 3rd quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company’s stock worth $298,008,000 after acquiring an additional 9,240,434 shares during the last quarter. American Century Companies Inc. raised its holdings in shares of Kenvue by 22.4% during the 3rd quarter. American Century Companies Inc. now owns 37,046,660 shares of the company’s stock worth $601,267,000 after acquiring an additional 6,781,640 shares during the period. Finally, Amundi grew its holdings in shares of Kenvue by 82.5% in the second quarter. Amundi now owns 14,509,890 shares of the company’s stock valued at $305,446,000 after purchasing an additional 6,559,261 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Up 1.2%

NYSE:KVUE opened at $17.61 on Tuesday. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The stock’s fifty day moving average is $17.98 and its two-hundred day moving average is $17.15. The stock has a market capitalization of $33.75 billion, a price-to-earnings ratio of 22.87, a price-to-earnings-growth ratio of 3.95 and a beta of 0.51. The company has a quick ratio of 0.68, a current ratio of 0.96 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.05. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The business had revenue of $3.78 billion during the quarter, compared to analysts’ expectations of $3.68 billion. During the same period in the previous year, the firm posted $0.26 earnings per share. The company’s revenue was up 3.2% on a year-over-year basis. Research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th were paid a dividend of $0.2075 per share. The ex-dividend date was Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a yield of 4.7%. Kenvue’s dividend payout ratio is 107.79%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Citigroup lifted their target price on shares of Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. UBS Group raised their target price on Kenvue from $17.00 to $19.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 18th. Canaccord Genuity Group upped their price target on Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a research note on Wednesday, February 18th. Finally, Jefferies Financial Group downgraded Kenvue from a “buy” rating to a “hold” rating and cut their price objective for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Three equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $19.58.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.